135 related articles for article (PubMed ID: 28752433)
21. Effect of escalating doses of recombinant human granulocyte colony-stimulating factor (filgrastim) on circulating neutrophils in healthy subjects.
Borleffs JC; Bosschaert M; Vrehen HM; Schneider MM; van Strijp J; Small MK; Borkett KM
Clin Ther; 1998; 20(4):722-36. PubMed ID: 9737832
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and adverse events following 5-day repeated administration of lenograstim, a recombinant human granulocyte colony-stimulating factor, in healthy subjects.
Akizuki S; Mizorogi F; Inoue T; Sudo K; Ohnishi A
Bone Marrow Transplant; 2000 Nov; 26(9):939-46. PubMed ID: 11100272
[TBL] [Abstract][Full Text] [Related]
23. Single-Dose Pharmacokinetics, Pharmacodynamics and Immunogenicity, and Multiple-Dose Immunogenicity of INTP5 (Pegfilgrastim Biosimilar) Versus Reference Pegfilgrastim in Healthy Subjects.
Singh I; Attrey A; Garg A; Patel R; Jose V
Clin Drug Investig; 2021 Jan; 41(1):29-42. PubMed ID: 33236287
[TBL] [Abstract][Full Text] [Related]
24. PLAG (1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol) augments the therapeutic effect of pegfilgrastim on gemcitabine-induced neutropenia.
Yoo N; Lee HR; Shin SH; Sohn KY; Kim HJ; Han YH; Chong S; Kim MH; Yoon SY; Kim JW
Cancer Lett; 2016 Jul; 377(1):25-31. PubMed ID: 27105612
[TBL] [Abstract][Full Text] [Related]
25. Pegfilgrastim.
Curran MP; Goa KL
Drugs; 2002; 62(8):1207-13; discussion 1214-5. PubMed ID: 12010086
[TBL] [Abstract][Full Text] [Related]
26. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma.
Vose JM; Crump M; Lazarus H; Emmanouilides C; Schenkein D; Moore J; Frankel S; Flinn I; Lovelace W; Hackett J; Liang BC
J Clin Oncol; 2003 Feb; 21(3):514-9. PubMed ID: 12560443
[TBL] [Abstract][Full Text] [Related]
27. In vivo pharmacokinetics and pharmacodynamics of positional isomers of mono-PEGylated recombinant human granulocyte colony stimulating factor in rats.
Kang JS; Lee KC
Biol Pharm Bull; 2013; 36(7):1146-51. PubMed ID: 23811564
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of glycosylated recombinant human granulocyte colony-stimulating factor (lenograstim) in healthy male volunteers.
Houston AC; Stevens LA; Cour V
Br J Clin Pharmacol; 1999 Mar; 47(3):279-84. PubMed ID: 10215752
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic and pharmacodynamic bioequivalence study of a pegfilgrastim biosimilar INTP5 in healthy subjects.
Singh I; Patel A; Patel R; Jose V
Cancer Chemother Pharmacol; 2018 Aug; 82(2):329-337. PubMed ID: 29948023
[TBL] [Abstract][Full Text] [Related]
30. Meta-analysis of Pharmacokinetic/Pharmacodynamic Results of 3 Phase 1 Studies with Biosimilar Pegfilgrastim.
Gattu S; Wang J; Bellon A; Schelcher C; Nakov R; Arani R
Clin Pharmacol Drug Dev; 2021 Oct; 10(10):1130-1141. PubMed ID: 34350732
[TBL] [Abstract][Full Text] [Related]
31. Pharmacodynamics, safety, and immunogenicity of Pelmeg
Wessels H; Lehnick D; Höfler J; Jankowsky R; Chamberlain P; Roth K
Pharmacol Res Perspect; 2019 Oct; 7(5):e00507. PubMed ID: 31417681
[TBL] [Abstract][Full Text] [Related]
32. A randomized, double-blind trial of pegfilgrastim versus filgrastim for the management of neutropenia during CHASE(R) chemotherapy for malignant lymphoma.
Kubo K; Miyazaki Y; Murayama T; Shimazaki R; Usui N; Urabe A; Hotta T; Tamura K
Br J Haematol; 2016 Aug; 174(4):563-70. PubMed ID: 27072050
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic and Pharmacodynamic Bioequivalence of Pegfilgrastim-cbqv Delivered via a Prefilled Autoinjector and Prefilled Syringe in Healthy Male Participants.
Tang H; Civoli F; Tatarewicz S; Vandenkoornhuyse N; Finck B
Adv Ther; 2023 Nov; 40(11):4889-4906. PubMed ID: 37707674
[TBL] [Abstract][Full Text] [Related]
34. Preclinical evaluation of a biobetter candidate: Pharmacokinetics and pharmacodynamics of GX-G3 in healthy and neutropenia-induced rats.
Kim YJ; Ertan-Ahmed S; Capan Y; Yang SI
Drug Dev Res; 2019 Sep; 80(6):807-813. PubMed ID: 31294492
[TBL] [Abstract][Full Text] [Related]
35. A large multicentre, randomized, double-blind, cross-over study in healthy volunteers to compare pharmacokinetics, pharmacodynamics and safety of a pegfilgrastim biosimilar with its US- and EU-reference biologics.
Bellon A; Wang J; Skerjanec A; Velinova M; Dickerson D; Sabet A; Ngo L; O'Reilly T; Tomek C; Schussler S; Schier-Mumzhiu S; Gattu S; Koch SD; Schelcher C; Dobreva M; Boldea A; Nakov R; Otto GP
Br J Clin Pharmacol; 2020 Jun; 86(6):1139-1149. PubMed ID: 32022282
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetic and pharmacodynamic modelling of the novel human granulocyte colony-stimulating factor derivative Maxy-G34 and pegfilgrastim in rats.
Scholz M; Engel C; Apt D; Sankar SL; Goldstein E; Loeffler M
Cell Prolif; 2009 Dec; 42(6):823-37. PubMed ID: 19780759
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of pegfilgrastim in children with cancer receiving myelosuppressive chemotherapy.
André N; Kababri ME; Bertrand P; Rome A; Coze C; Gentet JC; Bernard JL
Anticancer Drugs; 2007 Mar; 18(3):277-81. PubMed ID: 17264759
[TBL] [Abstract][Full Text] [Related]
38. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.
Holmes FA; O'Shaughnessy JA; Vukelja S; Jones SE; Shogan J; Savin M; Glaspy J; Moore M; Meza L; Wiznitzer I; Neumann TA; Hill LR; Liang BC
J Clin Oncol; 2002 Feb; 20(3):727-31. PubMed ID: 11821454
[TBL] [Abstract][Full Text] [Related]
39. A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim.
Brekkan A; Lopez-Lazaro L; Yngman G; Plan EL; Acharya C; Hooker AC; Kankanwadi S; Karlsson MO
AAPS J; 2018 Aug; 20(5):91. PubMed ID: 30112626
[TBL] [Abstract][Full Text] [Related]
40. Bioequivalence of two recombinant granulocyte colony-stimulating factor products after subcutaneous injection in healthy volunteers.
Lubenau H; Sveikata A; Gumbrevicius G; Macijauskiene J; Fokas V; Kazlauskas S; Janulionis V
Int J Clin Pharmacol Ther; 2009 Apr; 47(4):275-82. PubMed ID: 19356394
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
